Perceive Biotherapeutics completes VOY-101 Phase 2a JOURNEY enrollment in geographic atrophy
Perceive Bio completes 94-eye VOY-101 enrollment for geographic atrophy. Examine trial design, safety, competition and the 2027 readout.
Pharma & Biotech
Pharma & Biotech
Ocugen doses first patient in Phase 3 OCU410 gene therapy trial for geographic atrophy
Ocugen has begun the 237-patient Phase 3 ArMaDa3 trial of OCU410, a one-time gene therapy for geographic atrophy after Phase 2 treatment reduced lesion growth by 31% at 12 months.